总胆固醇与他汀治疗对ARDS患者死亡率的影响:SAILS与HARP-2试验的二次分析
该研究为SAILS和HARP-2两项多中心试验的二次分析,纳入脓毒症相关ARDS患者,测量入组时冻存血浆总胆固醇,比较最低胆固醇四分位(SAILS <69 mg/dL,HARP-2 <44 mg/dL)与其他四分位与60天死亡率及药物效应的关联。SAILS中678例可测胆固醇,HARP-2中509例(其中384例有脓毒症),两试验入组时中位胆固醇均为97 mg/dL。低胆固醇与更高的APACHE III评分、休克患病率(SAILS)及更高的SOFA评分、升压药使用(HARP-2)相关。SAILS中低胆固醇患者接受瑞舒伐他汀后死亡风险更高(OR 2.23,95%CI 1.06-4.77,p=0.02;交互p=0.02);HARP-2中低胆固醇患者接受辛伐他汀后死亡率较低,但未达统计学显著(OR 0.44,95%CI 0.17-1.07,p=0.06;交互p=0.22)。作者认为,尽管胆固醇水平很低,辛伐他汀治疗似乎安全并可能降低该组死亡率,而瑞舒伐他汀与伤害相关。
要点
- 脓毒症相关ARDS患者入组时胆固醇普遍偏低,SAILS与HARP-2中位总胆固醇均为97 mg/dL。
- 最低胆固醇四分位(SAILS <69 mg/dL,HARP-2 <44 mg/dL)患者病情更重:SAILS中APACHE III更高、休克更常见;HARP-2中SOFA评分更高、升压药使用更多。
- SAILS中低胆固醇患者接受瑞舒伐他汀后死亡风险升高(OR 2.23,95%CI 1.06-4.77,p=0.02;交互p=0.02)。
- HARP-2中低胆固醇患者接受辛伐他汀后死亡率较低,但未达统计学显著(OR 0.44,95%CI 0.17-1.07,p=0.06;交互p=0.22)。
- 作者认为,尽管胆固醇水平很低,辛伐他汀似乎安全并可能降低该组死亡率,而瑞舒伐他汀与伤害相关。
适用人群与场景
- 脓毒症相关ARDS患者,来自SAILS和HARP-2两项多中心随机试验的入组人群;SAILS中678例、HARP-2中509例(其中384例有脓毒症)可测得胆固醇。
诊断标准与关键阈值
- 低胆固醇定义为最低四分位:SAILS <69 mg/dL,HARP-2 <44 mg/dL;与其他四分位比较。
处置流程与药物剂量
- SAILS试验将ARDS患者随机分配至瑞舒伐他汀或安慰剂,HARP-2试验随机分配至辛伐他汀或安慰剂,疗程均最长28天。
研究设计与关键结果
- 二次分析纳入SAILS 678例、HARP-2 509例(其中384例有脓毒症)可测胆固醇的ARDS患者,两试验入组时中位胆固醇均为97 mg/dL。
- SAILS中低胆固醇与更高APACHE III评分和休克患病率相关;HARP-2中低胆固醇与更高SOFA评分和升压药使用相关。
- SAILS中低胆固醇患者接受瑞舒伐他汀后死亡风险更高(OR 2.23,95%CI 1.06-4.77,p=0.02;交互p=0.02)。
- HARP-2中低胆固醇患者接受辛伐他汀后死亡率较低,但未达统计学显著(OR 0.44,95%CI 0.17-1.07,p=0.06;交互p=0.22)。
证据类型、等级与局限
- 证据类型:两项多中心随机对照试验(SAILS、HARP-2)的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,尽管胆固醇水平很低,辛伐他汀治疗似乎安全并可能降低脓毒症相关ARDS低胆固醇患者的死亡率,而瑞舒伐他汀与伤害相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Two acute respiratory distress syndrome (ARDS) trials showed no benefit for statin therapy, though secondary analyses suggest inflammatory subphenotypes may have a differential response to simvastatin. Statin medications decrease cholesterol levels, and low cholesterol has been associated with increased mortality in critical illness. We hypothesized that patients with ARDS and sepsis with low cholesterol could be harmed by statins.
METHODS: Secondary analysis of patients with ARDS and sepsis from two multicenter trials. We measured total cholesterol from frozen plasma samples obtained at enrollment in Statins for Acutely Injured Lungs from Sepsis (SAILS) and Simvastatin in the Acute Respiratory Distress Syndrome (HARP-2) trials, which randomized subjects with ARDS to rosuvastatin versus placebo and simvastatin versus placebo, respectively, for up to 28 days. We compared the lowest cholesterol quartile (< 69 mg/dL in SAILS, < 44 mg/dL in HARP-2) versus all other quartiles for association with 60-day mortality and medication effect. Fisher's exact test, logistic regression, and Cox Proportional Hazards were used to assess mortality.
RESULTS: There were 678 subjects with cholesterol measured in SAILS and 509 subjects in HARP-2, of whom 384 had sepsis. Median cholesterol at enrollment was 97 mg/dL in both SAILS and HARP-2. Low cholesterol was associated with higher APACHE III and shock prevalence in SAILS, and higher Sequential Organ Failure Assessment score and vasopressor use in HARP-2. Importantly, the effect of statins differed in these trials. In SAILS, patients with low cholesterol who received rosuvastatin were more likely to die (odds ratio (OR) 2.23, 95% confidence interval (95% CI) 1.06-4.77, p = 0.02; interaction p = 0.02). In contrast, in HARP-2, low cholesterol patients had lower mortality if randomized to simvastatin, though this did not reach statistical significance in the smaller cohort (OR 0.44, 95% CI 0.17-1.07, p = 0.06; interaction p = 0.22).
CONCLUSIONS: Cholesterol levels are low in two cohorts with sepsis-related ARDS, and those in the lowest cholesterol quartile are sicker. Despite the very low levels of cholesterol, simvastatin therapy seems safe and may reduce mortality in this group, though rosuvastatin was associated with harm.
参考来源
- Pienkos SM, Moore AR, Guan J, et al. Effect of total cholesterol and statin therapy on mortality in ARDS patients: a secondary analysis of the SAILS and HARP-2 trials. Crit Care. 2023. PMID: 36978134. doi:10.1186/s13054-023-04387-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。